Head-to-head · Cost-Efficiency Index
Pallas Health vs Synergy Rx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Pallas Health
Shoppers comfortable paying a quarter at a time who want the whole cost stated before signup, and who are not looking for a month-to-month exit.
Visit Pallas HealthSynergy Rx
People who want a genuine brand-name route and maximum clinician access, and will accept getting a quote by inquiry.
Visit Synergy RxThe verdict
Pallas Health takes it, leading the Cost-Efficiency Index 74 to 72. Prices both molecules openly and bills them in 12-week blocks — $597 and $897 up front, with no monthly option to fall back on. Synergy Rx still earns a C — People who want a genuine brand-name route and maximum clinician access, and will accept getting a quote by inquiry.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Pallas Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Pallas Health | Synergy Rx |
|---|---|---|
| Cost-Efficiency Index | 74/100 | 72/100 |
| Semaglutide / mo | $199/mo average — Pallas's own figure for $597 billed every 12 weeks, its only cadence; $139 covers the first 4 weeks | From $199/mo |
| Tirzepatide / mo | $299/mo average — Pallas's own figure for $897 billed every 12 weeks, its only cadence; $179 covers the first 4 weeks | From $349/mo |
| Semaglutide / yr (modeled) | $2,388 | $2,388 |
| Tirzepatide / yr (modeled) | $3,588 | $4,188 |
| Coverage | Most states | Not disclosed |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #47 | #53 |
Pallas Health
74/100Where the value is
- Both molecules are priced publicly, with the charged block stated rather than only a monthly average
- A genuinely reduced first cycle — $139 semaglutide and $179 tirzepatide for the first four weeks
- Runs a Spanish-language lander as well as the English site, which most of this field does not
The tradeoffs
- There is no monthly rung. The only cadence is a 12-week block paid up front — $597 or $897 — so the advertised 'per month' figure is arithmetic rather than a payment anyone makes
- A 12-week cycle is 4.33 charges a year, not 4, so a year costs more than four times the block
Synergy Rx
72/100Where the value is
- Prescribes FDA-approved brand Wegovy, Ozempic and Mounjaro when clinically appropriate, not compounded only
- Unlimited appointments, unlimited messaging and 24/7 access to a dedicated clinical team
- A $100 welcome credit applied at checkout, and FSA/HSA eligible
The tradeoffs
- Prices are published as bare “Starting at” figures with no billing cycle or term attached, so a full-year cost still cannot be modeled before an inquiry
- At $349/mo tirzepatide sits roughly $100 above the compounded median we track
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.